Surveillance and management of diabetes in a CMHC population

Psychiatric Services

Volumn 58, Issue 9, 2007, Pages 1151-1153

  Srihari, Vinod H ^a,b   Tek, Cenk ^a,b   Chwastiak, Lydia A ^a,b   Woods, Scott W ^a,b   Steiner, Jeanne L ^a,b  

^a Yale University School of Medicine   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ARIPIPRAZOLE; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; DISEASE CLASSIFICATION; HEALTH CARE MANAGEMENT; HUMAN; MENTAL DISEASE; MENTAL HEALTH CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMARKETING SURVEILLANCE; ADULT; COMMUNITY MENTAL HEALTH CENTER; CROSS-SECTIONAL STUDY; FEMALE; HEALTH SURVEY; MALE; MIDDLE AGED; UNITED STATES;

ADULT; COMMUNITY MENTAL HEALTH CENTERS; CONNECTICUT; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE;

EID: 34848852251     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.58.9.1151     Document Type: Article

References (15)

1. Cowie CC, Rust KF, Byrd-Holt DD, et al: Prevalence of diabetes and impaired fasting glucose in adults in the US population: national health and nutrition examination survey 1999-2002. Diabetes Care 29:1263-1268, 2006
2. Citrome L, Jaffe A, Levine J, et al: Incidence, prevalence, and surveillance for diabetes in New York state psychiatric hospitals, 1997-2004. Psychiatric Services 57:1132-1139, 2006
3. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601, 2004
4. American Diabetes Association: Standards of medical care for patients with diabetes (position statement). Diabetes Care 22 (suppl 1):S33-S50, 1999
5. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 27:5S-10, 2004
6. Woods SW, Sullivan MC, Neuse EC, et al: Racial and ethnic effects on antipsychotic prescribing practices in a community mental health center. Psychiatric Services 54:177-179, 2003
7. Bushe C, Holt R: Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. British Journal of Psychiatry Supplement 47:S67-S71, 2004
8. Chwastiak LA, Rosenheck RA, McEvoy JP, et al: Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. Psychiatric Services 57:1102-1109, 2006
9. Beaton SJ, Nag SS, Gunter MJ, et al: Adequacy of glycemic, lipid, and blood pressure management for patients with diabetes in a managed care setting. Diabetes Care 27:694-698, 2004
10. Unwin N, Shaw J, Zimmet P, et al: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabetic Medicine 19:708-723, 2002
11. Nasrallah HA, Meyer JM, Goff DC, et al: Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research 86:15-22, 2006
12. Barr RG, Nathan DM, Meigs JB, et al: Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Annals of Internal Medicine 137:263-272, 2002
13. Marshall SM, Flyvbjerg A: Prevention and early detection of vascular complications of diabetes. BMJ 333:475-480, 2006
14. Druss BG, Rohrbaugh RM, Levinson CM, et al: Integrated medical care for patients with serious psychiatric illness: a randomized trial. Archives of General Psychiatry 58:861-868, 2001
15. Cohn TA, Sernyak MJ: Metabolic monitoring for patients treated with antipsychotic medications. Canadian Journal of Psychiatry 51:492-501, 2006